Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04287361
Other study ID # RECHMPL19_0501
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 30, 2019
Est. completion date January 31, 2020

Study information

Verified date March 2020
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

•Background: Intravenous clonazepam is the most widely used first-line benzodiazepine in Europe for the initial management of status epilepticus in children.

The guidelines of the "Société de reanimation de langue francaise" (SRLF) and the "société française de médecine d'urgence" (SFMU) published in 2018 recommend an initial loading dose of 0.015 mg / kg of clonazepam in this situation (maximum 1.5 mg).

To our knowledge, there is no specific study of the efficacy of clonazepam according to the dose used.

Objective: To compare the effectiveness of the initial loading dose of clonazepam in children treated for status epilepticus

•Methods: Monocentric retrospective study including children < 16 years who have benefited from an initial loading dose of clonazepam in the context of status epilepticus treated at the Montpellier University Hospital between January 2016 and June 2019.

The investigators collected data from medical records (clinic, treatment , evolution) and compared these according to the dosage of clonazepam used.

•Discussion: Among the benzodiazepines used in the first-line treatment of pediatric status epileptic, lorazepam and midazolam are the most widely used drugs in the world.

Lorazepam is not so much used in Europe because the injectable form is not available for a daily use. Conversely, clonazepam is used in a large number of European countries but is rarely used in the United States due to the lack of an injectable form.

About the tolerance of treatment, except overdose situations, clonazepam is a drug well tolerated in the pediatric populatin. The main side effects of clonazepam are respiratory depression and impaired alertness.

To our knowledge, this study is the first to examine the efficacy depending on the initial loading dosage of clonazepam in children status epilepticus.


Recruitment information / eligibility

Status Completed
Enrollment 310
Est. completion date January 31, 2020
Est. primary completion date January 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 16 Years
Eligibility Inclusion criteria:

An individual must fulfill all of the following criteria in order to be eligible for study enrollment:

- Aged under 16 years

- Status epilepticus taken care of at the CHU de Montpellier

Exclusion criteria

? No loading dose of clonazepam

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Efficacy of intravenous clonazepam
Efficacy of intravenous clonazepam

Locations

Country Name City State
France Uh Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary effectiveness in stopping seizures The primary endpoint was clinical cessation of seizures, which was defined as the absence of clinical signs of seizures immediately following the injection of clonazepam. 1 day
Secondary need for a second dose of clonazepam need for a second dose of clonazepam 1 day
Secondary duration of seizure duration of seizure (minutes) 1 day
Secondary type of seizures type of seizures (focal, generalized); 1 day
Secondary aetiologies ; aetiologies (idiopathic, symptomatic) 1 day
Secondary pre-hospital treatment used pre-hospital treatment used 1 day
Secondary whether or not to use a dose greater than one milligram whether or not to use a dose greater than one milligram 1 day
Secondary introduction of a maintenance dose introduction of a maintenance dose 1 day
Secondary using another antiepileptic drug using another antiepileptic drug (phenobarbital, fosphenytoin, thiopental) 1 day
Secondary Hospitalization in an intensive care or resuscitation unit Hospitalization in an intensive care or resuscitation unit 1 day
Secondary Rate of hospitalization in conventional sector Rate of hospitalization in conventional sector 1 day
Secondary introduction of antiepileptic treatment after treatment introduction of antiepileptic treatment after treatment 1 day